全文获取类型
收费全文 | 688篇 |
免费 | 61篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 41篇 |
妇产科学 | 6篇 |
基础医学 | 94篇 |
口腔科学 | 18篇 |
临床医学 | 124篇 |
内科学 | 182篇 |
皮肤病学 | 14篇 |
神经病学 | 7篇 |
特种医学 | 71篇 |
外科学 | 29篇 |
综合类 | 26篇 |
一般理论 | 2篇 |
预防医学 | 39篇 |
眼科学 | 1篇 |
药学 | 45篇 |
肿瘤学 | 50篇 |
出版年
2022年 | 3篇 |
2021年 | 6篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 8篇 |
2014年 | 13篇 |
2013年 | 19篇 |
2012年 | 25篇 |
2011年 | 29篇 |
2010年 | 17篇 |
2009年 | 30篇 |
2008年 | 34篇 |
2007年 | 30篇 |
2006年 | 37篇 |
2005年 | 34篇 |
2004年 | 30篇 |
2003年 | 28篇 |
2002年 | 22篇 |
2001年 | 18篇 |
2000年 | 29篇 |
1999年 | 17篇 |
1998年 | 21篇 |
1997年 | 30篇 |
1996年 | 20篇 |
1995年 | 15篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 15篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 8篇 |
1987年 | 13篇 |
1986年 | 11篇 |
1985年 | 27篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 12篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1976年 | 2篇 |
1975年 | 5篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1891年 | 1篇 |
排序方式: 共有752条查询结果,搜索用时 0 毫秒
61.
62.
At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine (dTpa) versus tetanus–diphtheria (Td) + monovalent acellular pertussis (pa) were seroprotected against diphtheria (≥0.016 IU/mL Vero cell assay) and tetanus (≥0.1 IU/mL ELISA assay) in 94.4% and 96.2%, respectively (dTpa), compared with 93.7% and 90.6% (Td + pa). Anti-FHA, anti-PT and anti-PRN antibodies (≥5 EL.U/mL) were maintained in 100%, 89.5% and 95.0% of dTpa versus 100%, 85.5% and 90.6% of pa vaccine recipients. At 5 years post boosting, antibody levels to diphtheria and tetanus are similar amongst adults receiving a dTpa or dT, and pertussis antibodies remain above pre-booster levels in at least 85%. 相似文献
63.
64.
Swinnen LJ LeBlanc M Grogan TM Gordon LI Stiff PJ Miller AM Kasamon Y Miller TP Fisher RI 《Transplantation》2008,86(2):215-222
BACKGROUND: Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. METHODS: Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for 1 week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m(2)/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. RESULTS: Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR. Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection. Only 1 of 13 (7%) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years. CONCLUSIONS: Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to RI as initial therapy. Chemotherapy resulted in 57% durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab. 相似文献
65.
Lode H Allewelt M Balk S De Roux A Mauch H Niederman M Schmidt-Ioanas M 《Infection》2007,35(3):143-149
Abstract
Objectives: Bacteria play a leading role in acute exacerbations of chronic obstructive pulmonary disease (COPD), but we lack predictors
of bacterial etiology. We developed a prediction model for infection with gram-negative enteric bacteria (GNEB) and Pseudomonas aeruginosa.
Methods: Clinical presentation, sputum characteristics, microbial sputum patterns, lung function and previous and concomitant medication
were prospectively recorded in patients with moderate to severe exacerbation of COPD. Risk factors for a specific bacterial
etiology were c alculated and a prediction model developed.
Results: A total of 193 patients with acute exacerbation were included. In 121 (62.6%) of them a microbial etiology could be identified,
most frequently Haemophilus influenzae (32 strains), Streptococcus pneumoniae (22 strains) and P. aeruginosa (12 strains). Multivariate analysis identified severe airflow obstruction and use of systemic steroids as predictors for
exacerbation due to gram-negative enteric bacilli and P. aeruginosa. A prediction model including FEV1 < 35% of predicted value, systemic steroid use and prior antibiotic therapy within preceeding
3 months had a negative predictive of 89%, being a helpful tool in excluding patients at risk of exacerbation due to gram-negative
enteric bacilli and P. aeruginosa when all criteria are absent.
Conclusion: A simple prediction model based on three factors may identify COPD patients at low risk for exacerbations with gram-negative
enteric bacilli and P. aeruginosa. Bacterial Etiology in COPD Exacerbations. 相似文献
66.
Tejedor JC Omeñaca F García-Sicilia J Esporrín C Molina V Marés J Muro M Sanjuan P Méndez M Teixidor R Enrubia M García-Corbeira P Boceta R Jacquet JM Schuerman L;Spanish DTPa-IPV/Hib- Study Group 《The Pediatric infectious disease journal》2006,25(10):943-945
Children 17-20 months of age (N = 344) received a diphtheria-tetanus toxoids-acellular pertussis (DTPa)-inactivated poliovirus vaccine (IPV)/Haemophilus influenzae (Hib) booster after a 3-dose primary vaccination course with DTPa-hepatitis B vaccine-IPV/Hib plus conjugate meningococcal C vaccine-CRM. Seroprotection rates were >80% (diphtheria, tetanus, hepatitis B, polio and polyribosylribitol phosphate) before and > or =96.6% (diphtheria, tetanus, polio and polyribosylribitol phosphate) after booster vaccination. The booster was well-tolerated (fever >39.5 degrees C after <2% of doses; large swelling reactions after 6.3% of doses). 相似文献
67.
急性淋巴细胞白血病(上) 总被引:2,自引:0,他引:2
急性淋巴细胞白血病是淋巴前体细胞异常引起的恶性疾病,儿童与成人均可能发生。儿童发病高峰2~5岁。有效治疗的稳步进展使本病在儿童中的治愈率80%以上,同时为新的治疗方案提供了良机,新方案将保留我们在白血病无病生存病例中获得的治疗经验,同时减轻当前强化治疗方案中的毒副作用。 相似文献
68.
神经外科中高渗盐注射液应用研究进展 总被引:1,自引:0,他引:1
控制脑水肿和颅内压(ICP)升高是神经外科围手术期治疗的重要组成部分.颅脑创伤、动脉梗塞、静脉高压/梗塞、大脑内出血、蛛网膜下腔出血、肿瘤和术后脑组织水肿的治疗过程中ICP的控制都是决定患者预后的关键因素.虽然利用渗透压脱水药物是控制ICP的最基础的工具,但却缺乏前瞻性研究以指导其运用,高渗盐被认为是甘露醇的替代物,早期的数据表明每种药的用药指征最终取决于ICP的病因.在这篇综述中,我们总结了有关高渗盐(HS)治疗颅内高压的相关数据,以及这些数据和我们有关HS的经验是如何指导目前的ICP治疗的. 相似文献
69.
Javier Bola?os-Meade Elizabeth Garrett-Mayer Leo Luznik Viki Anders Jennifer Webb Ephraim J Fuchs Carol Ann Huff William Matsui Ivan M Borrello Robert Brodsky Yvette L Kasamon Lode J Swinnen Ian W Flinn Richard F Ambinder Richard J Jones Allan D Hess Georgia B Vogelsang 《Biology of blood and marrow transplantation》2007,13(10):1185-1191
The results of blood or marrow transplantation in patients with chemorefractory aggressive lymphoma, that is, those not responding to conventional-dose chemotherapy at the time of transplant, have been poor. The relapse rate has been high after autologous bone marrow transplant, whereas allogeneic transplantation has been associated with excessive transplant-related toxicity. Administration of cyclosporine after autologous transplantation can induce an autoreactive syndrome that resembles graft-versus-host disease (GVHD). This syndrome, named autologous graft-versus-host disease, has clear antitumor activity in animal models that can be enhanced by the addition of cytokines such as gamma-interferon and interleukin-2. A randomized, prospective study was conducted to evaluate the antitumor effect of autologous graft-versus-host disease induced with cyclosporine, and augmented by the administration of gamma-interferon and interleukin-2 in patients with chemorefractory Hodgkin and aggressive non-Hodgkin lymphomas. Fifty-one patients were randomized, 24 to the autologous GVHD induction arm, and 27 to the noninduction arm after autologous transplant using mobilized peripheral blood stem cell (PBSC) grafts. There were no differences in treatment-related mortality, overall and event-free survival (OS, EFS) between both groups; however, in the induction arm, GVHD developed only in 4 patients. The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts. 相似文献
70.
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. 总被引:1,自引:1,他引:1 下载免费PDF全文
H Lode R Wiley G Hffken J Wagner K Borner 《Antimicrobial agents and chemotherapy》1987,31(10):1491-1496
In a randomized prospective study, 66 patients with serious bacterial infections--mainly lower respiratory tract infections--were treated with either imipenem plus cilastatin (32 patients) or ciprofloxacin (34 patients); 30 patients in each group were evaluable for efficacy. Substantial underlying disease was present in most of the patients; pathogens isolated prior to treatment (77 isolates) consisted mainly of members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and streptococci. Of the etiologic bacteria, 67% were eradicated by ciprofloxacin treatment and 79% by imipenem therapy; however, two patients (6.7%) failed in the ciprofloxacin group, and six patients (20%) did not respond to imipenem treatment (P = 0.25). All patients with therapeutic failures suffered from severe fatal underlying diseases, which had substantial impact on the outcome of treatment. Therapeutic drug monitoring in the ciprofloxacin patients revealed higher concentrations in serum at days 4 and 8 in comparison with day 1 of treatment, indicating that steady-state conditions were reached between days 1 and 4. The total number of side effects was relatively high--eight imipenem patients (25%) and six ciprofloxacin patients (18%) had reactions. Treatment had to be discontinued due to adverse reactions for three ciprofloxacin patients and two imipenem patients. Major side effects in both groups were gastrointestinal and central nervous system-related symptoms. In terms of clinical and bacteriological efficacy and safety, there was no statistical difference between the two groups, and both groups gave good to excellent results for bacterial infections that were difficult to treat. 相似文献